What Is the Best Treatment for Lyme Disease?

When patients come to the office with Lyme disease, many have already been treated — yet they’re still sick. Others are newly diagnosed, overwhelmed by strange symptoms and uncertain about what lies ahead.

The question most often asked is:

“What’s the best treatment?”

---

There’s No One-Size-Fits-All Answer

Lyme disease can affect the brain, nerves, joints, heart, and immune system — and no two patients present exactly alike.

That’s why treatment is typically tailored to the full clinical picture, not just a checklist or laboratory result.

For some individuals, early treatment leads to rapid recovery. Others experience delayed diagnosis, relapsing symptoms, or overlapping co-infections that complicate care.

---

Clinical Decision-Making in Lyme Disease

Effective treatment often depends on several factors:

• How long symptoms have been present
• Whether symptoms were recognized early or delayed for months
• Whether symptoms relapsed after prior treatment
• Whether co-infections such as Babesia or Bartonella may be involved
• Whether neurologic, cardiac, or autonomic symptoms are present

For some patients, a standard antibiotic course is sufficient.

Others may require:

• Longer treatment durations
• Use of multiple antibiotics, especially in neurologic Lyme disease
• Targeted treatment for co-infections
• Supportive care including probiotics, sleep support, anti-inflammatory strategies, and nutritional optimization

---

Common Antibiotics Used for Lyme Disease

The choice of antibiotics depends on disease stage, symptom pattern, affected systems, and individual response.

Common oral antibiotics include:

• Tetracyclines
  Doxycycline
  Minocycline (Minocin)
  Tetracycline
• Beta-lactams
  Amoxicillin
  Penicillin VK
  Cefuroxime (Ceftin)
  Cefdinir (Omnicef)
• Macrolides
  Azithromycin (Zithromax)
  Clarithromycin (Biaxin)
  Sometimes combined with hydroxychloroquine to enhance intracellular activity

Intravenous antibiotics used in more severe neurologic or cardiac Lyme disease may include:

• Ceftriaxone (Rocephin)
• Cefotaxime (Claforan)

---

Treating Co-Infections: Babesia and Bartonella

Babesia

Babesia is a malaria-like protozoan parasite not effectively treated with doxycycline.

Treatment commonly includes:

• Atovaquone (Mepron or Malarone)
• Combined with azithromycin (Zithromax)

Alternative regimens for more severe or relapsing cases may include artemisinin-based compounds or quinine-containing therapies.

Emerging therapies such as tafenoquine (Arakoda) have shown laboratory and animal-model activity against Babesia microti. Tafenoquine has been used off-label in select refractory or immunocompromised cases but remains under investigation.

Because tafenoquine can trigger hemolytic anemia in patients with G6PD deficiency, screening is required before use.

Bartonella

Bartonella is classically associated with cat scratch disease but is increasingly discussed as a potential co-infection in Lyme disease.

Common antibiotic approaches may include:

• Tetracyclines (doxycycline, minocycline)
• Macrolides (azithromycin, clarithromycin)
• Rifampin
• Bactrim as part of combination therapy

Note: Physicians remain divided on the role of Bartonella in tick-borne illness. Some consider it clinically significant in persistent cases, while others remain skeptical. Its role continues to be investigated.

---

Persister-Directed Strategies

Laboratory studies suggest that Borrelia burgdorferi may adopt dormant or slow-growing “persister” forms that appear more tolerant to conventional antibiotics.

This has led to investigation of non-traditional and repurposed therapies aimed at these forms.

Some clinicians have explored these approaches alongside conventional therapy, though their clinical role remains uncertain.

The significance of persister forms in persistent Lyme symptoms remains an active area of research.

---

Approaches Targeting Biofilms

Laboratory studies have also shown that Borrelia may form biofilm-like structures that could reduce antibiotic penetration or alter immune response.

This has led some clinicians to explore biofilm-disrupting agents as adjunctive therapies.

Human evidence remains limited, and these approaches are generally considered investigational or integrative rather than established standards of care.

More clinical research is needed to clarify their effectiveness and safety.

---

Treating the Whole Person

Lyme disease can affect multiple body systems and often requires more than antimicrobial treatment alone.

Comprehensive care may include attention to:

• Neuropsychiatric symptoms — anxiety, depression, panic, insomnia, OCD
• Autonomic dysfunction — dizziness, rapid heartbeat, sweats, gastrointestinal motility problems
• Cognitive impairment — brain fog, memory issues, concentration difficulty
• Fatigue and post-exertional symptom worsening
• Muscle and joint pain
• Head pressure and migraines
• Light and sound sensitivity
• Vision changes or eye discomfort
• Tingling, numbness, or burning sensations
• Air hunger or shortness of breath
• Hormonal or menstrual changes
• Sleep disturbance
• Functional limitations affecting work, school, or social life

Successful care often depends on monitoring symptoms carefully, adjusting treatment when necessary, and supporting both physical and mental recovery.

---

What Do the Guidelines Say?

Some physicians follow a more standardized approach based on Infectious Diseases Society of America (IDSA) guidelines.

These recommendations typically include:

• 10–21 days of doxycycline for early Lyme disease
• Up to 28 days of IV ceftriaxone for neurologic or cardiac Lyme disease
• No additional antibiotics for persistent symptoms after standard therapy

Under this model, persistent symptoms are generally attributed to post-infectious immune or inflammatory changes rather than active ongoing infection.

This approach may work well for many individuals diagnosed and treated early.

However, patients with delayed diagnosis, relapsing illness, co-infections, or complex neurologic symptoms may require more individualized strategies.

---

Frequently Asked Questions

What is the best antibiotic for Lyme disease?
The best antibiotic depends on disease stage, symptom pattern, co-infections, and individual response. Doxycycline is commonly used early, but other antibiotics may be appropriate in different clinical settings.

Can Lyme disease require more than one antibiotic?
Yes. Some patients with neurologic symptoms or co-infections may receive combination therapy.

Does Lyme disease always respond to short-term treatment?
Many patients improve with standard treatment, particularly when diagnosed early. Others may experience persistent or relapsing symptoms requiring reassessment.

What is the role of co-infections in Lyme treatment?
Co-infections such as Babesia or Bartonella may alter symptom patterns and influence treatment choices.

Are biofilm or persister therapies proven treatments?
No. These approaches remain investigational and are still being studied.

---

Final Thoughts

The best treatment is the one that fits the patient.

Symptoms. History. Timing. Response to therapy.

Some individuals recover quickly. Others require longer or more complex care.

When symptoms persist, listening carefully to the patient, reassessing the diagnosis, and remaining open to evolving evidence can make a meaningful difference.

If recovery has not come yet, there may still be additional options to explore.

---

---

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention